Intensive research into new treatment strategies for PD has highlighted GLP-1 receptor agonists as potential new therapeutic agents.18The possibility that these drugs may yield neuroprotective benefits is supported by robust preclinical studies suggesting that they affect pathological pathways relevant to PD. The gene discussed is GLP1R; the disease is Parkinson disease.